ketoconazole and ropivacaine

ketoconazole has been researched along with ropivacaine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Alm, C; Arlander, E; Bertilsson, L; Bielenstein, M; Böttiger, Y; Carrillo, JA; Ekström, G; Gustafsson, LL	1

Trials

1 trial(s) available for ketoconazole and ropivacaine

Article	Year
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clinical pharmacology and therapeutics, 1998, Volume: 64, Issue:5 Topics: Adult; Amides; Anesthetics, Local; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Ketoconazole; Male; Mixed Function Oxygenases; Reference Values; Ropivacaine; Time Factors	1998

Article

Year

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.

Clinical pharmacology and therapeutics, 1998, Volume: 64, Issue:5

Topics: Adult; Amides; Anesthetics, Local; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Ketoconazole; Male; Mixed Function Oxygenases; Reference Values; Ropivacaine; Time Factors

1998

Other Studies

2 other study(ies) available for ketoconazole and ropivacaine

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.

Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012